Biocompatibility of Intracanal Medications Based on Calcium Hydroxide

Table 2

Number of inflammatory cells and giant cells/mm² of the capsule adjacent to the implants in the subcutaneous.

ߙ	Inflammatory cells		Giant cells
	7 days	30 days	7 days	30 days
Calen	2,795.10 ± 939.90^a,1	960.64 ± 433.22^a,2	4.14 ± 0.90^a,1	0.92 ± 0.18^a,2
UltraCal XS	2,397.66 ± 613.14^a,1	975.99 ± 227.71^a,2	6.00 ± 1.03^b,1	2.77 ± 1.05^b,2
Hydropast	2,248.10 ± 315.41^a,1	1,407.82 ± 870.89^a,2	8.77 ± 1.46^c,1	1.37 ± 0.87^c,2

Values are expressed as mean ± standard deviation.
Equal letters indicate no statistically significant difference (𝑃>0.05) between the materials in the same experimental period.
Different numbers indicate difference statistically significant (𝑃≤0.05) of each material in the different experimental periods.